null

VivoGenie Anti-Human PD-L1 (Atezolizumab) - Fc Reduced Biosimilar (IVMB0467)

SKU:
IVMB0467
Antibody Type:
In Vivo Biosimilar
Endotoxin Level:
Low Endotoxin
Applications:
In Vivo
Disease Area:
Cancer
€909

Description

system_update_altDatasheetsystem_update_altMSDS
Product Name:Anti-Human PD-L1 (Atezolizumab)
SKU:IVMB0467
Size:500 µg
Antibody Type:Biosimilar Recombinant Human Monoclonal Antibody
Clone:RG7446
Target:PD-L1
Isotype:Human IgG
Host Species:Human
Reactivity:Human
Applications:FC
Expression Host:HEK-293 Cells
FC Effector Activity:Muted
Synonyms:Programmed Death Ligand 1, B7-H1, PD-L1, CD274
Product Concentration:≥ 5.0 mg/ml
Purity:≥95% by SDS Page
Immunogen:Unknown
Endotoxin Level:< 1.0 EU/mg as determined by the LAL method
Applications and Recommended Usage:FC The suggested concentration for Atezolizumab biosimilar antibody for staining cells in flow cytometry is ≤ 0.25 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
Antigen Distribution:PD-L1 is present on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes.
Formulation:This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Specificity:This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Atezolizumab. Atezolizumab recognizes an epitope on mouse PD-L1. This product is for research use only.
Additional Applications Reported In Literature:WB

PD-1 is a 50-55 kD member of the B7 Ig superfamily. PD-1 is also a member of the extended CD28/CTLA-4 family of T cell regulators and is suspected to play a role in lymphocyte clonal selection and peripheral tolerance. The ligands of PD-1 are PD-L1 and PD-L2, and are also members of the B7 Ig superfamily. PD-1 and its ligands negatively regulate immune responses. PD-L1, or B7-Homolog 1, is a 40 kD type I transmembrane protein that has been reported to costimulate T cell growth and cytokine production. The interaction of PD-1 with its ligand PD-L1 is critical in the inhibition of T cell responses that include T cell proliferation and cytokine production. PD-L1 has increased expression in several cancers. Inhibition of the interaction between PD-1 and PD-L1 can serve as an immune checkpoint blockade by improving T-cell responses In vitro and mediating preclinical antitumor activity. Within the field of checkpoint inhibition, combination therapy using anti-PD1 in conjunction with anti-CTLA4 has significant therapeutic potential for tumor treatments. PD-L2 is a 25 kD type I transmembrane ligand of PD-1. Via PD-1, PD-L2 can serve as a coinhibitor of T cell functions. Regulation of T cell responses, including enhanced T cell proliferation and cytokine production, can result from mAbs that block the PD-L2 and PD-1 interaction.

Ligand/Receptor:PD-1 (PDCD1)
Regulatory Status:Research Use Only (RUO). Non-Therapeutic.
Product Preparation:Recombinant biosimilar antibodies are manufactured in an animal free facility using onlyin vitroprotein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Pathogen Testing:To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
Storage and Handling:Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Research Area:Biosimilars

Related Products